TrialBlood2016

Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors.

Preetesh Jain et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.